GENETIC SUSCEPTIBILITY AND HEALTH EFFECTS OF OCCUPATIONAL EXPOSURE TO NITROAROMATIC COMPOUNDS IN AMMUNITION INDUSTRY (B)

By

Zayet HH1, Zawilla NH1, Yousry SM2 and Abdelsamea AA1

¹Department of Occupational and Environmental Medicine, ² Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University.

Abstract

Introduction: In factory workers, exposure to nitroaromatic compounds has been linked to many adverse health effects. Aim of work: To study the role of polymorphisms of Glutathione S-transferase (GST) gene as an effect modifier in relation to nitroaromatic induced health hazards. Materials and methods: The study was conducted on 40 workers as an exposed group comprising all workers engaged in ammunition production in a military factory in Helwan area, and a control group of 40 workers. All participants were subjected to an occupational and medical history questionnaire with full clinical examination, slit lamp examination, ECG scanning and laboratory investigations that included: liver and kidney functions, complete blood picture and serum 8-OHdG. Genetic study of GST gene polymorphism was done for the whole population. Multiplex PCR was performed for determination of GSTM1 and GSTT1 genes polymorphisms in the isolated DNAs, while PCR -Restriction Fragment Length Polymorphism (PCR- RFLP) was performed for GSTP1 gene polymorphisms. Results: Regarding frequency distribution of GST genes, in the exposed workers, intact gene of GST (M, T) and the wild GST (P) genes were more prevalent (57.5%, 65% and 62.5% respectively). However, in the control group, the intact gene of GST (M) and the wild GST (P) genes were more prevalent (95% and 77.5% respectively). In the exposed group regarding GST genes polymorphism, null GSTM gene group were predisposed to flushing, lower levels of Hematocrit value and Hb levels and blood urea. GSTP mutation group showed highly significant elevation of ALT and AST levels compared with intact gene group, while significant higher prevalence of ischemic heart diseases and level of ALT in GSTT null gene carriers on the other hand a significant higher mean level of creatinine and lower mean level of AST, was noted among exposed workers with GSTT nun null gene carriers. **Conclusion:** Genetic polymorphism in members of the GST gene family may be considered as an effect modifier and as genetic susceptibility for some nitroaromatic compounds health hazards. **Recommendations:** Further studies are recommended on a larger scale to study the net effect of multiple contributing genes.

Key words: Ammunition workers, Nitroaromatic health hazards, GST genes and Gene environment interaction.

Introduction

Nitroaromatic compounds have been reported as toxic, mutagenic and carcinogenic. They are used in multiple applications as pharmaceuticals, antimicrobial agents, food additives, pesticides, explosives, dyes and raw materials in several industrial processes (Oliveira et al., 2010).

TNT is one of the most recalcitrant and toxic of all the military explosives used (Padda et al., 2003). It is used in military shells, bombs, and grenades, in industrial uses, and in underwater blasting (Oliveira et al., 2010). TNT has accumulated in areas of manufacturing, storage, and decommissioning over recent decades. Various government agencies, such as the EPA have listed TNT as a priority pollutant and have recommended that it should be removed from contaminated sites to prevent environmental and health problems (Van Aken, 2009).

Despite the strong causal associations between certain occupational exposures and related health hazards, still there are differences in disease incidence between workers that cannot be accounted for by differences in exposures or work practices. Genetic polymorphisms account for some of these differences, thus should be included as relevant variables in study design and analysis (NIOSH, 2004).

Glutathione S-transferase (GST) enzymes comprise a family of phase II detoxifying metabolic enzymes best known for their ability to catalyze the conjugation of the reduced form of glutathione (GSH) to xenobiotic substrates (Atkinson Babbitt. and 2009), thus preventing their interaction with crucial cellular proteins and nucleic acids (Hayes et al., 2005 and Josephy, 2010). It is an important detoxifying mechanism ensuring more soluble substrates and allowing them to

be removed from the cell then excreted via urine or bile (Josephy, 2010 and Oakley, 2011). Moreover, they detoxify reactive chemical species by catalyzing their conjugation to GSH thus forms a protection against chemical hazards (Setiawan et al., 2000). The most well characterized GST classes have been named alpha (GSTA), mu (GSTM), pi (GSTP) and theta (GSTT) (Di Pietro et al., 2010).

Being encoding for GST enzymes that have a prominent role in neutralizing the toxic effects of TNT and other nitroaromatic compounds, GST gene family polymorphisms thus, predispose exposed persons more to the toxicity of these compounds, (Tamaki et al., 2011).

GSTM gene deletion may be one of the important hereditary factors for susceptibility to TNT hazards. Such deletion was reported to be closely correlated to TNT induced cataract (Xu et al., 2001).

Workers **GST** carrying the polymorphic genotype are supposed susceptible to be more some nitroaromatic compounds health hazards thus studying individual susceptibility (genetic polymorphisms of nitroaromatic compounds metabolizing enzymes such as GST) is one of the variables of bio monitoring paradigm (Sabbioni et al., 2006).

Aim of work

To study the role of polymorphisms of Glutathione S-transferase (GST) gene as an effect modifier in relation to nitroaromatic induced health hazards.

Materials and methods

Study design: It is a case control study.

Study place and duration of the study: this work has been conducted in a military ammunition factory in Helwan area, South of Cairo from June 2014 to Jan 2016.

Study sample: The exposed group comprised of 40 morning-shift workers (whole population) directly exposed to nitroaromatic compounds through engagement in ammunition production and maintenance line and fulfilling eligibility for inclusion in the study. The control group included 40 workers of both sex also randomly selected from the administration department in Cairo University Hospitals with no history of exposure to nitroaromatic compounds

or genotoxic substances and matched the exposed group as regards age, sex, smoking and socioeconomic status.

Inclusion criteria: All workers exposed to nitroaromatic compounds in a military ammunition factory for at least the preceding 5 years.

Exclusion criteria for both groups were workers with current or treated viral hepatitis/ schistosomiasis, medical conditions as uncontrolled diabetes, alcohol consumption, on regular medication with nitrates and antioxidants supplements.

The studied groups were subjected to the following:

1-A self-designed questionnaire about general health status, exposure history, smoking and alcohol consuming habits, previous medical record, and present symptoms.

2. Clinical examination

 Vital signs (as blood pressure, pulse and respiratory rate), ocular examination (Visual acuity and slit lamp examination for cataract), cutaneous examination for discoloration and contact dermatitis, cardiac, chest, abdominal, and neurological examination.

- **3. Electro Cardio Gram (ECG)** was done to detect arrhythmias and cardiac ischemia.
- 4. Laboratory investigations 10cc of venous blood was taken from each subject through a venipuncture using a dry plastic syringe under aseptic conditions. The sample was then divided into four clean tubes; the first two contained EDTA one for CBC and the other for DNA study (incubated at -20), the third was heparinized for lead analysis, while the last was dry not containing any chemicals for the rest of investigations. All samples were transported in an ice box to the laboratory.

I. Blood lead level:

We used the flame atomic absorption spectrophotometry (model M6) (WHO, 2011).

- Π. Complete blood picture,
- **III.** Kidney function tests (urea, creatinine)
- IV. Liver enzymes (ALT, AST).
- V. Human 8-OHdG Elisa kit:

ELISA kit 8-OHdG applies the quantitative sandwich enzyme immunoassay technique (Witherel et al., 1998).

VI. Determination of GSTM1, GSTT1 and GSTP1 gene polymorphisms:

1. DNA Extraction:

DNA extraction was done using Gene JETTM Genomic DNA Purification Kit- (Fermentas, Thermo Scientific, USA).

Principle:

The extraction of DNA from whole blood encompassed the lyses of proteins with proteinase K. Ribonucleic acid (RNA) is removed by treating the sample with RNase A. The lysate is then mixed with ethanol and loaded on the purification column where the DNA binds to the silica membrane. Impurities are effectively removed by washing the column with the prepared wash buffers. Genomic DNA is then eluted under low ionic strength conditions with the Elution Buffer.

2. Amplification of the extracted genomic DNA by Polymerase Chain Reaction (PCR):

A- principle: PCR consists of repetitive cycles of DNA denaturation, primer annealing and extension by DNA polymerase. Each cycle produces complementary DNA strands to which the primers bind before the polymerase affects another extension in the next cycle of amplification. Accordingly, the products of each cycle are doubled, generating an exponential increase the overall number of copies synthesized. This results in a highly sensitive method that allows multiple reactions from a very small number of initial DNA sequences (Serrano et al., 2004).

B- Multiplex PCR for determination of GSTM1 and GSTT1 polymorphisms in the isolated DNAs:

Multiplex PCR method was used to determine GSTM1 and GSTT1 polymorphisms in the isolated DNA as described before (Magno et al.,2009).

For GSTM1 polymorphism: Forward primer (5'-GAA CTC CCT GAAAAG CTAAAG C-3') and reverse primer (5'-GTT GGG CTC AAA TAT ACG GTG G-3') were used. For GSTT1 polymorphism: Forward primer (5'-TTC CTT ACT GGT CCT CAC ATC TC-3') and reverse primer (5'- TCA CCG GAT CAT GGC CAG CA-3') were used.

As an internal control, a fragment of the human β-globin gene was also amplified using the forward primer (5'-GAA GAG CCA AGG ACA GGT AC-3') and the reverse primer (5'-CAA CTT CAT CCA CGT TCA CC-3').

The final reaction mixture consisted of 2µL DNA, 25µL Dream Taq Green PCR master mix (Fermentas, Thermo Scientific), 20pmol of each of forward and reverse primers, and was made up to 50µL with PCR quality water.

C- The PCR was carried out in thermal cycler (Perkin-Elmer).

The final PCR products from coamplification of GSTM1 (157 bp) and GSTT1 (480 bp) were visualized on an ethidium bromide-stained 2.0% agarose gel. The subjects were classified as either (+), when at least one copy of the gene was detected, or (–) when they showed a null genotype. Heterozygous and homozygous individuals with GSTM1 (GSTM1+/– and GSTM1+/+)

or GSTT1 (GSTT1+/- and GSTT1+/+) were reported to present similar enzymes activity and expression levels so they were grouped together (Bell et al., 1993).

D- PCR-Restriction Fragment
Length Polymorphism (PCR-RFLP) for detection of GSTP1 gene
polymorphisms: PCR-RFLP is a
sensitive measure of genetic variation
between individuals. DNA is treated
with a restriction endonuclease that
cut at specific sequence or restriction
sites. This produces a large number
of restriction fragments of many
different lengths.

GSTP1 polymorphism was detected by PCR-RFLP method as described previously (Zhong et al., 2006).

The primer sequences used were; forward primer: 5'-GAG GAA ACT GAG ACC CAC TGA G-3') and reverse primer: 5'-AGC CCC TTT CTT TGT TCA GCC-3').

The final reaction mixture consisted of 2μL DNA, 1.5μL Dream Taq Green PCR master mix (Fermentas, Thermo Scientific), 20pmol of each of forward and reverse primers, and was made up

to 25 µL with PCR quality water. The PCR was carried out in thermal cycler (Perkin-Elmer). The restricted PCR products were electrophoresed through 2% ethidium bromide stained agarose gel, and visualized by ultraviolet light.

The amplified fragment digestion with Alw26I restriction enzyme can give rise to either two fragments at 329 and 107 bp which indicates the presence of wild-type GSTP1 (IIe/IIe), or two fragments at 222 and 107 bp which indicates the presence of the homozygous mutant type (Val/Val), or three fragments at 329, 222, and 107 bp, which indicates the presence of heterozygous mutant type (Ile/Val).

3. Detection of the PCR products:

- A. Preparation of 2.0% agarose gel.
- B. Samples preparation and loading: Samples were prepared for loading by adding 1 μ l 1x loading buffer to 5μ 1 of the PCR reaction mixture. Five μ 1 of each prepared samples were slowly loaded into the sample wells.
- **C. Performing the electrophoresis:** The lid was carefully placed on the

gel electrophoresis apparatus then the gel apparatus was connected so that the negative electrode (cathode) is nearest to the sample wells at the start of electrophoresis at 150 volts and 250 milliamperes for 20 minutes.

D. Detection of the site of the bands in agarose gel using ultra-violet transillumination: The most convenient method for visualizing DNA on agarose gel is by staining with the fluorescent dye ethidium bromide. DNA- ethidium bromide complexes absorb ultra-violet light at 260, 300 or 360 nm and emit at 590 nm in the red orange region of the visible spectrum.

Consent

Authors declare that a verbal consent was taken from the studied group, confidentiality was maintained.

Ethical approval

The study protocol was approved by the Ethical Committee of the Department of Occupational and Environmental Medicine, Faculty of Medicine, Cairo University.

Data management

Data was coded and entered using the statistical package SPSS version 15. Data was summarized using number and percent for qualitative data, Mean \pm SD for quantitative data which were normally distributed, while median and interquartile range for quantitative data which is not normally Comparison distributed. between groups were done using Chi-square test for qualitative data, independent simple t-test for quantitative data which are normally distributed, while parametrical Mann-Whitney test was

used for quantitative data which were not normally distributed. p-value less than 0.05 and less than 0.001were considered statistically significant and highly significant, respectively.

Results

The mean duration of work and exposure to nitroaromatic compounds among exposed workers was 31.55 years (± 2.68) and ranged (25-37). No statistically significant difference was found between the exposed and control groups as regards age, sex and smoking.

Table (1): Frequency distribution of GST (M, P and T) polymorphism among exposed and control groups.

		Exposed No=40		Control No=40		\mathbf{X}^2	р
		No	%	No	%		
CCTM	Null	17	42.5	2	5.0	15.53	<0.001**
GSTM	Nun-null	23	57.5	38	95.0	15.55	
GSTP	Mutant(Hetero)	15	37.5	9	22.5	2 142	0.143
	Wild	25	62.5	31	77.5	2.143	
GSTT	Null	14	35	23	57.5	4.072	40 044*
	Nun-null	26	65	17	42.5	4.073	<0.044*

Null: absent gene. Nun null: intact gene. Mutant (Hetero): Heterogenous mutation.

*Significant. **Highly significant.

Table 1 showed that among the exposed workers, intact gene of GST (M,T) and the wild GST (P) genes were more prevalent (57.5%, 65% and 62.5% respectively), However, among the control group, the intact gene of GST (M) and the wild GST (P) genes were the more prevalent (95% and 77.5% respectively).

Table (2): Frequency distribution of some clinical and cardiovascular manifestations among exposed workers with GSTM null and nunnull gene polymorphisms.

			GSTM null No =17		GSTM non-null No =23		X ²	p
			No	%	No	%		
a.	General	Anorexia, Nausea, Vomiting	6	35.3	2	8.7	4.322	0.038
		Metallic taste	8	47.1	10	43.5	051	0.822
		Bony aches	6	35.3	8	34.8	0.001	0.973
		Flushing	11	64.7	7	30.4	4.639	0.031*
		Memory troubles	7	41.2	4	17.4	2.774	0.096
		Easy fatigability	4	23.5	8	34.8	0.589	0.443
b.	Work accidents		3	17.6	6	26.1	0.399	0.527
c.	Eye	Cataract	9	52.9	10	43.5	0.351	0.935
		Diminution of vision	10	58.8	15	65.2	0.171	0.680
d.	Skin	Contact dermatitis	9	52.9	11	47.8	0.102	0.749
		Skin discoloration	9	52.9	11	47.8	0.102	0.749
e.	Respiratory	Bronchial hypersensitivity	10	58.8	16	69.6	0.496	0.481
		Allergic rhinitis	9	52.9	9	39.1	0.753	0.385
f.	Reproductive troubles		8	47.1	14	60.9	0.753	0.385
g.	Cardiovascular manifestations	IHD	9	52.9	8	34.8	1.319	0.251
		ECG changes	7	41.2	9	39.1	0.017	0.896
		Headache	11	64.7	11	47.8	1.125	0.289
		Dizziness	4	23.5	3	13	0.744	0.388
		HTN	8	47.1	9	39.1	0.251	0.616
SBP		Mean(SD)	132.06	(±18.63)	128.70 (0 (±16.04) 0.612		0.544
		Range	110	0-165	110-180		0.012	
	DBP	Mean(SD)	83.82	(±10.54)	.54) 80.87 (±9)		0.954	0.346
	DDI	Range	70-100		70-110		0.334	0.346

IHD: ischemic heart disease, HTN: Hypertension. cut off level of HTN is ≥140/90 (American heart association, 2014),SBP: Systolic blood pressure (mmHg), DBP: Diastolic blood pressure (mmHg), *Significant.

Table 2 showed significant higher prevalence of flushing among exposed workers with absent GST gene, while there was a non significant difference between exposed workers with GSTM null and nun null gene polymorphisms as regards the other manifestations.

Table (3): Complete blood picture, liver and kidney function, blood lead levels and serum 8OHdG results among exposed workers with GSTM null and nun null gene polymorphisms.

$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		1	1 37 11	., ,,			
Range 4.2-10.10 3.20-10.70 1.524 0.136			Null No =17	Non null No =23	t value	p	
RBCs (c/cmm) Range A.2-10.10 3.20-10.70 1.524	TLC	Mean(SD)	7.09(±2.13)	6.11(±1.92)		0.136	
Range 3.92-5.99 3.98-5.73 0.897 0.376	(c/cmm)	Range	4.2-10.10	3.20-10.70	1.524		
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	RBCs	Mean(SD)	4.87(±.0.51)	5(±0.41)	0.907	0.276	
Range 10.30-15.20 11.30-15.90 2.661 0.011 Hematocrit Mean(SD) 38.75(±4.26) 41.22(±3.53) 2.007 0.050* MCV (femtoliters) Range 70.30-88.70 67.20-95.10 1.398 0.170 MCH (pictograms) Range 23.50-31.60 21.20-33.70 1.764 0.086 MCHC (%) Mean(SD) 33.46(±1.50) 34(±1.51) 34(±1.51) 1.131 0.265 RDX Mean(SD) 14.42(±1.60) 13.83(±1.55) 1.170 0.249 Platelet Mean(SD) 236.41(±68.51) 229.04(±65.77) Range 128-362 130-376 1.442 0.149 ALT (IU/I) Mean(SD) 23.82(±12.94) 17.48(±7.87) Range 10-55 10-33 1.773 0.076 Creatinine (μmol/L) Range 22.49 25-50 2.935 0.006* Creatinine (μmol/L) Range 0.22-0.60 0.27-1.62 0.493 0.622 Range 22.27-1084 159.10-1156 Mean(SD) 12.19(±6.30) 13.19(±6.84) 0.493 0.622 Mean(SD) 12.1	(c/cmm)	Range	3.92-5.99	3.98-5.73	0.897	0.376	
Hematocrit Mean(SD) 38.75(±4.26) 41.22(±3.53) 2.007 0.050*	Hb	Mean(SD)	12.96(±1.33)	14.05(±1.24)	2 661	0.011*	
MCV (femtoliters) Mean(SD) 79.79(±5.41) 82.88(±7.84) 1.398 0.170 MCV (femtoliters) Mean(SD) 79.79(±5.41) 82.88(±7.84) 1.398 0.170 MCH (pictograms) Mean(SD) 26.71(±2.19) 28.19(±2.9) 1.764 0.086 MCHC (%) Mean(SD) 33.46(±1.50) 34(±1.51) 1.131 0.265 RDX Mean(SD) 14.42(±1.60) 13.83(±1.55) 1.170 0.249 RDX Mean(SD) 236.41(±68.51) 229.04(±65.77) 0.344 0.733 Platelet Mean(SD) 19.24(±3.93) 17.52(±5.82) 1.442 0.149 ALT (IU/I) Mean(SD) 19.24(±3.93) 17.52(±5.82) 1.442 0.149 AST (IU/I) Mean(SD) 23.82(±12.94) 17.48(±7.87) 1.773 0.076 Urea (mg/dl) Mean(SD) 31.12(±7.98) 38.39(±7.57) 2.935 0.006* Creatinine (μmol/L) Mean(SD) 0.96(±0.29) 1.10(±0.18) 1.807 0.079 Bilirubin (μmol/L) Mean	(g/dl)	Range	10.30-15.20	11.30-15.90	2.001	0.011	
Range 30.80-46.40 33.70-48.60 MCV (femtoliters) Range 70.30-88.70 67.20-95.10 1.398 0.170 MCH (pictograms) Range 23.50-31.60 21.20-33.70 1.764 0.086 MCHC (%) Range 30.20-36 30.80-35.90 1.131 0.265 RDX Range 12-18.40 12.10-18.80 1.170 0.249 Platelet Mean(SD) 236.41(±68.51) 229.04(±65.77) Range 128-362 130-376 1.442 0.149 ALT (IU/I) Range 13-25 10-30 1.442 0.149 AST (IU/I) Range 10-55 10-33 1.773 0.076 Urea (mg/dl) Range 23.49 25-50 2.935 0.006* Creatinine (μmol/L) Range 0.22-0.60 0.27-1.62 Range 0.22-0.60 0.27-1.62 Range 222.7-1084 159.10-1156 0.493 0.622 Mean(SD) 12.19(±6.30) 13.19(±6.84) 0.493 0.622 MCH (mol/L) Range 222.7-1084 159.10-1156 0.493 0.622 MCH (mol/L) Range 222.7-1084 159.10-1156 0.493 0.622 Mean(SD) 12.19(±6.30) 13.19(±6.84) 0.493 0.622 MCH (mol/L) Range 222.7-1084 159.10-1156 0.493 0.622 MCH (mol/L) Range 222.7-1084 159.10-1156 0.493 0.622 Mean(SD) 12.19(±6.30) 13.19(±6.84) 0.493 0.622 Manual (SD) 12.19(±6.30) 13.19(±6.84) 0.493 0.622 MCH (mol/L) Range 222.7-1084 159.10-1156 0.493 0.	Hamataanit	Mean(SD)	38.75(±4.26)	41.22(±3.53)	2.007	0.050*	
$\begin{array}{c} \text{(femtoliters)} & Range & 70.30-88.70 & 67.20-95.10 & 1.398 & 0.170 \\ \textbf{MCH} & Mean(SD) & 26.71(\pm 2.19) & 28.19(\pm 2.9) & 1.764 & 0.086 \\ \hline \textbf{MCHC} & Mean(SD) & 33.46(\pm 1.50) & 34(\pm 1.51) & 1.131 & 0.265 \\ \textbf{RDX} & Mean(SD) & 14.42(\pm 1.60) & 13.83(\pm 1.55) & 1.170 & 0.249 \\ \hline \textbf{Range} & 12-18.40 & 12.10-18.80 & 1.170 & 0.249 \\ \hline \textbf{Platelet} & Mean(SD) & 236.41(\pm 68.51) & 229.04(\pm 65.77) & 0.344 & 0.733 \\ \textbf{ALT} & (IU/I) & Mean(SD) & 19.24(\pm 3.93) & 17.52(\pm 5.82) & 1.442 & 0.149 \\ \hline \textbf{AST} & (IU/I) & Mean(SD) & 23.82(\pm 12.94) & 17.48(\pm 7.87) & 1.773 & 0.076 \\ \hline \textbf{Creatinine} & Mean(SD) & 31.12(\pm 7.98) & 38.39(\pm 7.57) & 2.935 & 0.006^{\circ} \\ \hline \textbf{Creatinine} & Mean(SD) & 0.96(\pm 0.29) & 1.10(\pm 0.18) & 1.807 & 0.079 \\ \hline \textbf{Bilirubin} & Mean(SD) & 0.36(\pm 0.13) & 0.58(\pm 0.42) & 2.089 & 0.037^{\circ} \\ \hline \textbf{Range} & 0.22-0.60 & 0.27-1.62 & 0.493 & 0.622 \\ \hline \textbf{Mean}(SD) & 12.19(\pm 6.30) & 13.19(\pm 6.84) & 0.493 & 0.622 \\ \hline \textbf{Mean}(SD) & 12.19(\pm 6.30) & 13.19(\pm 6.84) & 0.493 & 0.622 \\ \hline \textbf{Mean}(SD) & 12.19(\pm 6.30) & 13.19(\pm 6.84) & 0.493 & 0.622 \\ \hline \textbf{Mean}(SD) & 12.19(\pm 6.30) & 13.19(\pm 6.84) & 0.493 & 0.622 \\ \hline \textbf{Mean}(SD) & 12.19(\pm 6.30) & 13.19(\pm 6.84) & 0.493 & 0.622 \\ \hline \textbf{Mean}(SD) & 12.19(\pm 6.30) & 13.19(\pm 6.84) & 0.493 & 0.622 \\ \hline \textbf{Mean}(SD) & 12.19(\pm 6.30) & 13.19(\pm 6.84) & 0.493 & 0.622 \\ \hline \textbf{Mean}(SD) & 12.19(\pm 6.30) & 13.19(\pm 6.84) & 0.493 & 0.622 \\ \hline \textbf{Mean}(SD) & 12.19(\pm 6.30) & 13.19(\pm 6.84) & 0.493 & 0.622 \\ \hline \textbf{Mean}(SD) & 12.19(\pm 6.30) & 13.19(\pm 6.84) & 0.493 & 0.622 \\ \hline \textbf{Mean}(SD) & 12.19(\pm 6.30) & 13.19(\pm 6.84) & 0.493 & 0.622 \\ \hline \textbf{Mean}(SD) & 12.19(\pm 6.30) & 13.19(\pm 6.84) & 0.493 & 0.622 \\ \hline \textbf{Mean}(SD) & 12.19(\pm 6.30) & 13.19(\pm 6.84) & 0.493 & 0.622 \\ \hline \textbf{Mean}(SD) & 12.19(\pm 6.30) & 13.19(\pm 6.84) & 0.493 & 0.622 \\ \hline \textbf{Mean}(SD) & 12.19(\pm 6.30) & 13.19(\pm 6.84) & 0.493 & 0.622 \\ \hline \textbf{Mean}(SD) & 12.19(\pm 6.30) & 13.19(\pm 6.84) & 0.493 & 0.622 \\ \hline \textbf{Mean}(SD) & 12.19(\pm 6.30) & 13.19(\pm 6.84) & 0.493 & 0.622 \\ \hline \textbf{Mean}(SD) & 12.19(\pm 6.30) & 13.19(\pm 6.84) & 0.493 & 0.622 \\ \hline \textbf{Mean}(SD) & 12.19(\pm 6.30) & 13.1$	пешаюсти	Range	30.80-46.40	33.70-48.60	2.007	0.050	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	MCV	Mean(SD)	79.79(±5.41)	82.88(±7.84)		0.170	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	(femtoliters)	Range	70.30-88.70	67.20-95.10	1.398	0.170	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		Mean(SD)	26.71(±2.19)	28.19(±2.9)	1 764	0.096	
MCHC (%) Range $30.20\text{-}36$ $30.80\text{-}35.90$ 1.131 0.265 RDX Mean(SD) $14.42(\pm 1.60)$ $13.83(\pm 1.55)$ 1.170 0.249 Platelet Mean(SD) $236.41(\pm 68.51)$ $229.04(\pm 65.77)$ 0.344 0.733 ALT (IU/I) Mean(SD) $19.24(\pm 3.93)$ $17.52(\pm 5.82)$ 1.442 0.149 AST (IU/I) Mean(SD) $23.82(\pm 12.94)$ $17.48(\pm 7.87)$ 1.773 0.076 Urea (mg/dl) Mean(SD) $31.12(\pm 7.98)$ $38.39(\pm 7.57)$ 2.935 0.006° Creatinine (µmol/L) Mean(SD) $0.96(\pm 0.29)$ $1.10(\pm 0.18)$ 1.807 0.079 Bilirubin (µmol/L) Mean(SD) $0.36(\pm 0.13)$ $0.58(\pm 0.42)$ 2.089 0.037° 8OHdG (U/ml) Mean(SD) $744.98(\pm 333.67)$ $678.45(\pm 376.21)$ 0.493 0.622 Range $222.7-1084$ $159.10-1156$ 0.493 0.622	(pictograms)	Range	23.50-31.60	21.20-33.70	1./64	0.086	
RDX $Mean(SD)$ $14.42(\pm 1.60)$ $13.83(\pm 1.55)$ 1.170 0.249 Platelet $Mean(SD)$ $236.41(\pm 68.51)$ $229.04(\pm 65.77)$ 0.344 0.733 ALT (IU/I) $Mean(SD)$ $19.24(\pm 3.93)$ $17.52(\pm 5.82)$ 1.442 0.149 AST (IU/I) $Mean(SD)$ $23.82(\pm 12.94)$ $17.48(\pm 7.87)$ 1.773 0.076 Ast (IU/I) $Mean(SD)$ $23.82(\pm 12.94)$ $17.48(\pm 7.87)$ 1.773 0.076 Ast (IU/I) $Mean(SD)$ $31.12(\pm 7.98)$ $38.39(\pm 7.57)$ 2.935 0.006° Creatinine (µmol/L) $Mean(SD)$ $0.96(\pm 0.29)$ $1.10(\pm 0.18)$ 1.807 0.079 Bilirubin (µmol/L) $Mean(SD)$ $0.36(\pm 0.13)$ $0.58(\pm 0.42)$ 2.089 0.037° SOHdG (U/ml) $Mean(SD)$ $744.98(\pm 333.67)$ $678.45(\pm 376.21)$ 0.493 0.622 Mean(SD) $744.98(\pm 333.67)$ $678.45(\pm 376.21)$ 0.493 0.622	MCHC (%)	Mean(SD)	33.46(±1.50)	34(±1.51)	1 121	0.265	
RDX Range 12-18.40 12.10-18.80 1.170 0.249 Platelet Mean(SD) 236.41(±68.51) 229.04(±65.77) 0.344 0.733 ALT (IU/I) Mean(SD) 19.24(±3.93) 17.52(±5.82) 1.442 0.149 AST (IU/I) Mean(SD) 23.82(±12.94) 17.48(±7.87) 1.773 0.076 AST (IU/I) Mean(SD) 31.12(±7.98) 38.39(±7.57) 2.935 0.006* Urea (mg/dl) Mean(SD) 31.12(±7.98) 38.39(±7.57) 2.935 0.006* Creatinine (μmol/L) Mean(SD) 0.96(±0.29) 1.10(±0.18) 1.807 0.079 Bilirubin (μmol/L) Mean(SD) 0.36(±0.13) 0.58(±0.42) 2.089 0.037* 8OHdG (U/ml) Mean(SD) 744.98(±333.67) 678.45(±376.21) 0.493 0.622 Mean(SD) 12.19(±6.30) 13.19(±6.84) 0.493 0.622	MCHC (%)	Range	30.20-36	30.80-35.90	1.131		
Platelet Range 12-18.40 12.10-18.80 Platelet Mean(SD) 236.41(±68.51) 229.04(±65.77) 0.344 0.733 ALT (IU/I) Mean(SD) 19.24(±3.93) 17.52(±5.82) 1.442 0.149 AST (IU/I) Mean(SD) 23.82(±12.94) 17.48(±7.87) 1.773 0.076 AST (IU/I) Mean(SD) 31.12(±7.98) 38.39(±7.57) 2.935 0.006* Urea (mg/dl) Mean(SD) 31.12(±7.98) 38.39(±7.57) 2.935 0.006* Creatinine (μmol/L) Mean(SD) 0.96(±0.29) 1.10(±0.18) 1.807 0.079 Bilirubin (μmol/L) Mean(SD) 0.36(±0.13) 0.58(±0.42) 2.089 0.037* 8OHdG (U/ml) Mean(SD) 744.98(±333.67) 678.45(±376.21) 0.493 0.622 Mean(SD) 12.19(±6.30) 13.19(±6.84) 0.493 0.622	DDV	Mean(SD)	14.42(±1.60)	13.83(±1.55)	1 170	0.249	
Platelet Range 128-362 130-376 0.344 0.733 ALT (IU/I) Mean(SD) 19.24(±3.93) 17.52(±5.82) 1.442 0.149 AST (IU/I) Mean(SD) 23.82(±12.94) 17.48(±7.87) 1.773 0.076 Lorea (mg/dl) Mean(SD) 31.12(±7.98) 38.39(±7.57) 2.935 0.006* Creatinine (µmol/L) Mean(SD) 0.96(±0.29) 1.10(±0.18) 1.807 0.079 Bilirubin (µmol/L) Mean(SD) 0.36(±0.13) 0.58(±0.42) 2.089 0.037* 8OHdG (U/ml) Mean(SD) 744.98(±333.67) 678.45(±376.21) 0.493 0.622 Mean(SD) 12.19(±6.30) 13.19(±6.84) 0.493 0.622	KDA	Range	12-18.40	12.10-18.80	1.170		
Range 128-362 130-376 ALT (IU/I) Mean(SD) 19.24(±3.93) 17.52(±5.82) 1.442 0.149 AST (IU/I) Mean(SD) 23.82(±12.94) 17.48(±7.87) 1.773 0.076 Urea (mg/dl) Mean(SD) 31.12(±7.98) 38.39(±7.57) 2.935 0.006* Creatinine (µmol/L) Mean(SD) 0.96(±0.29) 1.10(±0.18) 1.807 0.079 Bilirubin (µmol/L) Mean(SD) 0.36(±0.13) 0.58(±0.42) 2.089 0.037* 8OHdG (U/ml) Mean(SD) 744.98(±333.67) 678.45(±376.21) 0.493 0.622 Mean(SD) 12.19(±6.30) 13.19(±6.84)	DI-4-1-4	Mean(SD)	236.41(±68.51)	229.04(±65.77)	0.244	0.733	
ALT (IU/I) Range 13-25 10-30 1.442 0.149 AST (IU/I) Mean(SD) 23.82(±12.94) 17.48(±7.87) 1.773 0.076 Urea (mg/dl) Mean(SD) 31.12(±7.98) 38.39(±7.57) 2.935 0.006* Creatinine (μ mol/L) Mean(SD) 0.96(±0.29) 1.10(±0.18) 1.807 0.079 Bilirubin (μ mol/L) Mean(SD) 0.36(±0.13) 0.58(±0.42) 2.089 0.037* 8OHdG (U/ml) Mean(SD) 744.98(±333.67) 678.45(±376.21) 0.493 0.622 Mean(SD) 12.19(±6.30) 13.19(±6.84) 0.493 0.622	Piateiet	Range	128-362	130-376	0.344		
Range 13-25 10-30 AST (IU/I) $Mean(SD)$ $23.82(\pm 12.94)$ $17.48(\pm 7.87)$ 1.773 0.076 Urea (mg/dl) Mean(SD) 31.12(\pmu7.98) $38.39(\pm 7.57)$ 2.935 0.006^* Creatinine (µmol/L) Mean(SD) $0.96(\pm 0.29)$ $1.10(\pm 0.18)$ 1.807 0.079 Bilirubin (µmol/L) Mean(SD) $0.36(\pm 0.13)$ $0.58(\pm 0.42)$ 0.037^* 8OHdG (U/ml) Mean(SD) $744.98(\pm 333.67)$ $678.45(\pm 376.21)$ 0.493 0.622 Mean(SD) $12.19(\pm 6.30)$ $13.19(\pm 6.84)$	ALT (IU/l)	Mean(SD)	19.24(±3.93)	17.52(±5.82)	1 442	0.149	
AST (IU/I) Range 10-55 10-33 1.773 0.076 Urea (mg/dl) Mean(SD) 31.12(\pm 7.98) 38.39(\pm 7.57) 2.935 0.006* Creatinine (µmol/L) Mean(SD) 0.96(\pm 0.29) 1.10(\pm 0.18) 1.807 0.079 Bilirubin (µmol/L) Mean(SD) 0.36(\pm 0.13) 0.58(\pm 0.42) 2.089 0.037* 8OHdG (U/ml) Mean(SD) 744.98(\pm 333.67) 678.45(\pm 376.21) 0.493 0.622 Mean(SD) 12.19(\pm 6.30) 13.19(\pm 6.84) 0.493 0.622		Range	13-25	10-30	1.442		
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	A COTE (TELU)	Mean(SD)	23.82(±12.94)	17.48(±7.87)	1 772	0.076	
Creatinine (μ mol/L) Mean(SD) 0.96(\pm 0.29) 1.10(\pm 0.18) 1.807 0.079 Bilirubin (μ mol/L) Mean(SD) 0.36(\pm 0.13) 0.58(\pm 0.42) 2.089 0.037* 8OHdG (U/ml) Mean(SD) 744.98(\pm 333.67) 678.45(\pm 376.21) 0.493 0.622 Mean(SD) 12.19(\pm 6.30) 13.19(\pm 6.84) 0.493 0.622	AST (10/1)	Range	10-55	10-33	1.//3		
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	TT (/ 15)	Mean(SD)	31.12(±7.98)	38.39(±7.57)	2.025	0.007*	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Orea (mg/ai)	Range	23-49	25-50	2.935	0.006	
Bilirubin (μ mol/L) Mean(SD) 0.36(±0.13) 0.58(±0.42) 2.089 0.037* 8OHdG (U/ml) Mean(SD) 744.98(±333.67) 678.45(±376.21) 0.493 0.622 Mean(SD) 12.19(±6.30) 13.19(±6.84) 0.493 0.622	Creatinine	Mean(SD)	0.96(±0.29)	1.10(±0.18)	1 007	0.070	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		Range	0.6-1.7	0.8-1.7	1.807	0.079	
(µmol/L) Range 0.22-0.60 0.27-1.62 2.089 0.037 8OHdG (U/ml) Mean(SD) 744.98(±333.67) 678.45(±376.21) 0.493 0.622 Range 222.7-1084 159.10-1156 0.493 0.622		Mean(SD)	0.36(±0.13)	0.58(±0.42)	2.000	0.027*	
(U/ml) Range 222.7-1084 159.10-1156 0.493 0.622 Mean(SD) 12.19(+6.30) 13.19(+6.84)		Range	0.22-0.60	0.27-1.62	2.089	0.037	
(U/ml) Range 222.7-1084 159.10-1156 0.493 0.622 Mean(SD) 12.19(+6.30) 13.19(+6.84)		Mean(SD)	744.98(±333.67)	678.45(±376.21)	0.402	0.622	
Mean(SD) 12.19(±6.30) 13.19(±6.84)		Range	222.7-1084	159.10-1156	0.493		
T 1/ /th	T 1/ /11	Mean(SD)	12.19(±6.30)	13.19(±6.84)	0.420	0.661	
Lead(μ g/dl) $Range$ 5.20-26.20 5-27 0.438 0.661	$\mathbf{Lead}(\mu \mathbf{g}/\mathbf{dl})$	Range	5.20-26.20	5-27	0.438	0.061	

TLC: total leucocytic count (cells per cubic millimeter (c/cmm), RBCs: red blood cells count (c/cmm), Hb: hemoglobin level (grams per deciliter), Hematocrit: The ratio of the volume of red cells to the volume of whole blood, MCV: mean corpuscular volume (femtoliters), MCH: Mean cell hemoglobin (pictograms), MCHC: Mean cell hemoglobin concentration (%), RDX: Red cell distribution width, ALT: alanine transaminase (IU/L), AST: aspartate transaminase (IU/L), Bilirubin: $(\mu \text{mol/L})$, Urea: (mg/dl), Creatinine $(\mu \text{mol/L})$, Lead $(\mu \text{g/dl})$, 8OHdG: 8hydroxyguanosine(U/ml),

*: Significant.

Table 3 showed significant higher mean values of Hb, hematocrit, urea and bilirubin among exposed workers with GSTM nun null gene compared with those with null gene. Non significant difference were found as regards the other studied laboratory parameters.

Table (4): Complete blood picture, liver and kidney functions, blood lead levels and serum 8OHdG results among exposed workers with GSTP mutant and wild gene polymorphisms.

		GSTP Mutant No =15	GSTP Wild No =25	t value	P	
	Mean(SD)	7.10(±1.92) 6.18(±2.08)			0.171	
TLC (c/cmm)	Range	4.30-10.70	3.20-10.10	1.395	0.171	
DDC (/	Mean(SD)	4.92(±.0.50)	4.96(±0.44)	0.204	0.763	
RBCs (c/cmm)	Range	3.92-5.99	3.98-5.73	0.304	0.763	
TTI (/ II)	Mean(SD)	13.50(±1.57)	13.64(±1.27)	217	0.753	
Hb (g/dl)	Range	10.30-15.80	11.40-15.90	317	0.753	
II	Mean(SD)	40.09(±4.53)	40.22(±3.74)	0.102	0.010	
Hematocrit	Range	30.80-48.60	33.40-48.00	0.102	0.919	
MCV (ft-lit)	Mean(SD)	81.62(±7.12)	81.54(±7.08)	0.026	0.071	
MCV (femtolitres)	Range	67.80-88.80	67.20-95.10	0.036	0.971	
MCII (nista anno)	Mean(SD)	27.50(±2.69)	27.59(±2.75)	0.102	0.019	
MCH (pictogram)	Range	22.70-31.60	21.20-33.70	0.103	0.918	
	Mean(SD)	33.67(±1.36)	33.83(±1.62)			
MCHC (%)	Range	31.50-35.70	30.20-36	0.317	0.753	
DDV	Mean(SD)	14.44(±1.84)	13.86(±1.39)	1 100	0.260	
RDX	Range	12.60-18.80	12-16.80	1.123	0.269	
DI_4_I_4	Mean(SD)	229.13(±59.07)	234(±71.21)	0.222	0.925	
Platelet	Range	128-337	130-376	0.222	0.825	
	Mean(SD)	21.87(±4.34)	16.12(±4.31)	2.226	. 0. 001**	
ALT (IU/L)	Range	16-30	10-23	3.226	< 0.001**	
A COTE (TILLY)	Mean(SD)	27.20(±12.98)	15.96(±6.09)	2 200	. 0. 001**	
AST (IU/L)	Range	13-55	10-28	3.298	< 0.001**	
II (Mean(SD)	35.07(±8.80)	35.44(±8.45)	0.122	0.905	
Urea (mg/dl)	Range	24-49	23-50	0.133	0.895	
Creatinine (µmol/L)	Mean(SD)	1.07(±0.28)	1.02(±0.22)	0.502	0.564	
	Range	0.80-1.70	0.6-1.6	0.582		
D. 1. (1/7)	Mean(SD)	0.37(±0.10)	0.55(±0.42)	1.010	0.212	
Bilirubin (μmol/L)	Range	0.22-0.52	0.27-1.62	1.010	0.312	
POUAC (II/ml)	Mean(SD)	640.28(±350.65)	756.59(±360.04)	1 256	0.175	
8OHdG (U/ml)	Range	159.10-1078	211.70-1156	1.356	0.175	
Load (ug/dl)	Mean(SD)	12.75(±6.85)	12.78(±6.51)	0.029	0.079	
Lead (µg/dl)	Range	5 -26.20	5-27	0.028	0.978	

Smoking index: number of packs per day× number of years, TLC: total leucocytic count (cells per cubic millimeter (c/cmm)), RBCs: red blood cells count (c/cmm), Hb: hemoglobin level (grams per deciliter), Hematocrit: The ratio of the volume of red cells to the volume of whole blood, MCV: mean corpuscular volume (femtoliters), MCH: Mean cell hemoglobin (pictograms), MCHC: Mean cell hemoglobin concentration (%), RDX: Red cell distribution width, ALT: alanine transaminase (IU/L), AST: aspartate transaminase (IU/L), 8OHdG: 8 hydroxyguanosine (U/ml), SBP: Systolic blood pressure (mmHg), DBP: Diastolic blood pressure (mmHg), **Highly significant.

Table 4 showed high statistically significant elevation in mean ALT and AST among those with GSTP mutant gene than in those with wild gene. No significant difference of the rest of laboratory data was noted.

Also, non-significant difference between exposed workers with GSTP mutant and wild gene polymorphisms as regards studied clinical and cardiovascular manifestation (data not shown).

Table (5): Frequency distribution of clinical manifestations among exposed workers with GSTT null and nun-null gene polymorphisms.

		GSTT null No =14		GSTT non- null No =26		X ²	p
		No	%	No	%		
a. General	Anorexia, nausea, vomiting	5	35.7	3	11.5	3.324	0.068
	Metallic taste	6	42.9	12	46.2	0.040	0.842
	Bony aches	7	50	7	26.9	2.130	0.144
	Flushing	9	64.3	9	34.6	3.237	0.072
	Memory troubles	4	28.6	7	26.9	0.012	0.911
	Easy fatigability	5	35.7	7	26.9	0.335	0.563
b. Work accidents	Accidents	0	0	9	34.6	6.253	0.012*
c. Eye	Cataract	7	50	12	46.2	.054	0.816
	Diminution of vision	10	71.4	15	57.7	0.733	0.392
d. Skin	Contact dermatitis	5	35.7	11	42.3	1.758	0.185
	Skin discoloration	9	64.3	11	42.3	1.758	0.185
e. Respiratory	Bronchial hypersensitivity	8	57.1	18	69.2	0.584	0.445
	Allergic rhinitis	6	42.9	12	46.2	0.040	0.842
f.Reproductive troubles		7	50	15	57.7	0.218	0.641
g. Cardiovascular manifestations							
IHD		9	64.3	8	30.8	4.183	0.04*
ECG changes		6	42.9	10	38.5	0.073	0.787
Headache		8	57.1	14	53.8	0.040	0.842
Dizziness		2	14.3	5	19.2	0.154	0.695
HTN		8	57.1	9	34.6	1.890	0.169
SBP	Mean(SD) Range	133.93 (±17.12) 110-165	128.08 (±16.98) 110-180			1.037	0.306
DBP	Mean(SD) Range	83.21 (±11.37) 70-100	81.54 (±8.81) 70-110			0.518	0.607

IHD: ischemic heart disease, HTN: Hypertension, cut off level of HTN is ≥140/90 (American heart association, 2014), SBP: Systolic blood pressure (mmHg), DBP: Diastolic blood pressure (mmHg). *significant.

Table 5 showed that work accidents are more prevalent among exposed workers with nun null GSTT gene (P=0.012) and significant higher prevalence of IHD among exposed workers with null GSTT carriers. No otherwise statistically significant variation in distribution of studied clinical and cardiovascular manifestations.

Among laboratory investigations a significant higher mean level of creatinine and lower mean level of AST, was noted among exposed workers with nun null GSTT carriers (data not shown).

Discussion

Being one of the genes coding for xenobiotic metabolizing enzymes and an important line of defense in the protection of cellular components against reactive species (Di Pietro et al., 2010), GST(Glutathione S-transferase) intact genes appear to form a protection mechanism against chemical hazards (Cai et al., 2001). Accordingly, the current study investigated the associations between genetic variability specific GST genes (GSTM1, in GSTT1, and GSTP1) and susceptibility to nitroaromatic compounds health hazards. It may explain why individuals with seemingly equal exposure to nitroaromatic compounds develop hazards in an unpredictable manner. Recognizing role of individual susceptibility aiding in improving workers health through identifying those more susceptible and setting better protective strategies for them.

On the other hand although GST reaction generally results in detoxification, in selected cases GST mediated conjugation may lead to a more toxic or mutagenic metabolite (Moore et al., 2010).

Within GST identified allelic gene classes variations, GSTM1, GSTT1 and GSTP1 allelic genes variation received the most attention in genetic epidemiological studies (Di Pietro et al., 2010) and thus they are our study targets.

Our work recorded the results of the comparison between intact and polymorphic forms of GST genes (GSTM, GSTP and GSTT) as regards all studied health effects.

GSTM gene polymorphism was studied were GSTM null gene group is that gathering individuals homozygous for the GSTM1 thus exhibiting loss of GSTM1 enzymatic activity (Table 2-3).

In this study significant lower values of Hb, Hematocrit value, Urea and Bilirubin levels were detected among the exposed workers with null gene in comparison with nunnull gene group (Table 3). These findings suggest that GSTM enzyme metabolizes nitroaromatic compounds studied to another form more toxic on hematological system but less toxic on the kidney and the liver .

Regarding clinical manifestations, significant higher prevalence of flushing among exposed population with absent GSTM gene, while non significant difference of the rest of clinical manifestations (Table 2). Sabbioni and his colleagues in 2006 studied many health hazards as inertia, nausea, insomnia, somnolence, dizziness, and

headache in relation to GST (GSTM, GSTP, GSTT) polymorphism. Workers with the GSTM1-null genotype also more often suffered from nausea and dizziness while those with a functional GSTM1 gene had a higher risk of suffering from headache and insomnia.

In order to detect the relationship between the activity of GSTs and susceptibility to Trinitrotoluene (TNT) cataract, Xu and his colleagues in 2002 studied the activity of GSTs enzymes among TNT cataract group in comparison with non TNT cataract and healthy non exposed groups. GSTs activity was significantly lower among TNT cataract group than in both other groups. Lowering in GSTs activity was correlated with GSTM gene deletion, concluding that TNT cataract and its stages are closely correlated with the activity of GSTs.

Xu and co-workers in 2001 examined the rates of GSTM gene deletion in 154 cases of TNT cataract patients, 41 cases of cataract patient by age or diabetes and 40 healthy persons. Results showed significantly higher rate of GSTM gene deletion in TNT cataract group than that of other two groups.

Close correlation of TNT cataract with GSTM gene deletion proving that GSTM gene deletion may be one of the important hereditary factors for TNT induced cataract susceptibility.

GSTP polymorphism was studied where GSTP mutant gene denotes single neoclotide polymorphism leading to amino acid substitution from Ile to Val changes catalytic activity of the GSTP1 enzymes (heterozygous genotypes as no homozygous mutant genotypes were found in our study). GSTP wild genotype denotes normal gene (Tables 4-5). Results showed significantly higher levels of liver enzymes (ALT, AST) and higher incidence of IHD among the group with mutant gene.

Among the exposed workers, chromosomal aberrations were more frequent among carriers of GSTP1 mutant allele than among wild gene group. These data suggest that GSTP1 variant allele may be associated with a lowered protection against reactive metabolites of TNT (Sabbioni et al., 2006).

The workers employed in a typical ammunition factory in China were examined as regards health effects as hepatomegaly, splenomegaly, cataract, mutagenicity and chromosomal aberrations and their relation to individual susceptibility. The genotypes polymorphism of GSTs (GSTM1, GSTT1, GSTP1) were determined. GST genotypes were found to be not associated with health effects (Sabbioni et al., 2007).

These results indicate that using a set of well-selected biomarkers may give more information regarding exposure and effect than routinely performed chemical measurements of pollutants in the air or on the skin (Sabbioni et al., 2006).

Personal susceptibility to occupational toxins in general and particularly nitroaromatic compounds is still a new era of research with very limited studies. Role of certain gene polymorphism on exposure to certain chemical couldn't be surely defined with one or few research studies. It needs a lot of supporting researches on the studied gene in relation to occupational exposures and in correlation with other xenobiotic metabolizing genes. It seems like connecting dots to define the figure clearly.

Conclusion

Despitethestrongcausalassociations between certain occupational exposures and related health hazards, still there are differences in disease prevalence between workers that cannot be accounted for by difference in exposures or work practices. Some of these differences are likely due to genetic polymorphisms that should be included as relevant variables in study design and analysis.

Recommendations

Further studies are recommended on a larger scale including bigger number of ammunition workers to confirm the previous findings related to the role of individual susceptibility in nitroaromatic compounds toxicity and to study the net effect of multiple contributing genes.

Conflict of interest

The authors declare that no conflicts of interest exists.

References

- 1. Atkinson HJ and Babbitt PC (2009): Glutathione transferases are structural and functional outliers in the thioredoxin fold. Biochemistry; 48 (46): 11108–16.
- Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL et al. (1993): Genetic risk and

- carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst; 85: 1159-1164.
- 3. Cai L, Yu SZ and Zhang ZF (2001): Glutathione S-transferase M1, T1 genotypes and the risk of gastric cancer: a case-control study. World journal of gastroenterology; 7(4): 506-509.
- Di Pietro G, Mango LA and Rios Santos F (2010): Glutathione S Transferase: an overview in cancer research. Expirt Opin Drug Metab Toxicol; 6:153-170.
- Hayes JD, Flanagan JU and Jowsey IR (2005): Glutathione transferases; Annu Rev Pharmacol Toxicol: 45:51-88.
- Josephy PD (2010): Genetic variations in human glutathione transferase enzymes: significance for pharmacology and toxicology. Hum Genomics Proteomics. available at:http://www. ncbi.nlm.nih.gov/pmc/articles/PMC2958679.
- 7. Magno LA, Talbot J, Talbot T, Borges Santos AM, Souza RP, et al. (2009): Glutathione s-transferase variants in a brazilian population. Pharmacology; 83(4): 231-236.
- Moore LE, Boffetta P, Karami S, Brennan P, Stewart PS, et al. (2010): Occupational trichloroethylene exposure and renal carcinoma risk: evidence of genetic susceptibility by reductive metabolism gene variants. Cancer research; 70(16): 6527-6536.
- NIOSH (National Institute of Occupational Safety and Hazards) (2004): Worker Health Chartbook. Respiratory Diseases. NIOSH Publication No. 2004-146: Available at: http:// www2a.cdc.gov/NIOSH-Chartbook/ch2/ch2-10-3.asp. (accessed: june, 2015).
- Oakley A (2011): Glutathione transferases: a structural perspective. Drug Metab. Rev; 43 (2): 138–151.
- Oliveira IM, Bonatto D, Henriques JA and Méndez-Vilas A (2010): Nitroreductases: enzymes with environmental, biotechnological and clinical importance. Reactions; 3: 6.
- 12. Padda R, Wang C, Hughes J, Kutty R and

- Bennett G (2003): Mutagenicity of nitroaromatic degradation compounds. Environ Toxicol Chem; 22: 2293-2297.
- Sabbioni G, Jones CR, Sepai O, Hirvonen A, Norppa H, et al. (2006): Biomarkers of exposure, effect, and susceptibility in workers exposed to nitrotoluenes. Cancer Epidemiol Biomarkers Prev; 15:559-566.
- 14. Sabbioni G, Sepai O, Norppa H, Yan H, Hirvonen A, et al (2007): Comparison of biomarkers in workers exposed to 2,4,6-trinitrotoluene. Biomarkers; 12: 21-37.
- Serrano NC, Paez C, Correa P and Anaya JM (2004): Endothelial nitric oxide synthase gene polymorphism in associated with systemic lupus erythematosis. J Rheumatol; 31: 2163-2168.
- Setiawan VW, Zhang ZF, Yu GP, Li YL, Lu ML, Tsai CJ et al., (2000): GSTT1 and GSTM1 null genotypes and the risk of gastric cancer: A case control study in a Chinese population. Cancer Epidemiology. Biomarkers & prevention; 9:73-80.
- 17. Tamaki Y, Arai T, Sugimura H, Sasaki T, Honda M, et al. (2011): Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan. Drug Metab Pharmacokinet; 26: 516-522.

- Van Aken B (2009): Transgenic plants for enhanced phytoremediation of toxic explosives. Curr Opin Biotechnol; 20:231-236.
- 19. WHO (World Health Organization) (2011): Brief guide to analytical methods for measuring lead in blood. Available at http://www.who.int/ipcs/assessment/public_health/lead_blood.
- Witherel HL, Hiatt RA, Replogle M and Parsonnet J (1998): Helicobacter pylori infection and urinary excretion of 8-hydroxy-2-deoxyguanosine, an oxidative DNA adducts. Cancer Epidemiology Biomarkers & Prevention; 7(2): 91-96.
- Xu J, Li C, Long Y, Zhan C and Wang W (2002): Study on GSTs activity in trinitrotoluene cataract. Journal of West China University of Medical Sciences; 33(1): 98-100.
- Xu J, Li C, Long Y, Zhan C, Wang W, et al. (2001): A study on relationship between glutathione S-transferase μ gene deletion and trinitrotoluene cataract susceptibility. Chinese Journal of Industrial Medicine; 14 (3):129-132.
- Zhong SL, Zhou S, Chen X, and Auang M (2006): Rapid determination of common mutations in glutathione S-transferase gene by PCR based methods in healthy chinese. Clin Chim Acta; 364: 205-208.